


WHEN DRUG UTILIZATION REVIEW BOARDS HURT CYSTIC FIBROSIS PATIENTS



State drug utilization review boards influence the accessibility of new treatments by shaping state Medicaid coverage decisions.



They can block access to medication by:



Justifying step therapy policies



Limiting access based on patients' age



Requiring invasive tests before patients can get their medication

Board members, usually appointed by the state, can be:



Health Care Providers



Consumer Representatives



Economists




Insurance Representatives



Pharmacists

When overly restrictive **drug utilization review boards** create barriers...



cystic fibrosis patients can't access breakthrough treatments.



Often, members are **NOT required to be experts** on the condition treated by the drug they are reviewing.

Drug utilization review boards should not cut costs at the expense of patients.